| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:54 UTC |
|---|
| HMDB ID | HMDB0015201 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Clonazepam |
|---|
| Description | Clonazepam, also known as klonopin or rivotril, belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. Clonazepam is a moderately basic compound (based on its pKa). Clonazepam is a potentially toxic compound. 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. However, its use can be limited by the development of tolerance and by sedation. |
|---|
| Structure | [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1 InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20) |
|---|
| Synonyms | | Value | Source |
|---|
| 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one | ChEBI | | 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one | ChEBI | | 5-(2-Chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one | ChEBI | | 5-(O-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one | ChEBI | | Clonazepamum | ChEBI | | Klonopin | Kegg | | Clonazepam fine granules | HMDB | | Clonazepam tablets | HMDB | | Chlonazepam | HMDB | | Rivotril | HMDB | | Antelepsin | HMDB |
|
|---|
| Chemical Formula | C15H10ClN3O3 |
|---|
| Average Molecular Weight | 315.711 |
|---|
| Monoisotopic Molecular Weight | 315.041068908 |
|---|
| IUPAC Name | 5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one |
|---|
| Traditional Name | clonazepam |
|---|
| CAS Registry Number | 1622-61-3 |
|---|
| SMILES | [O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1 |
|---|
| InChI Identifier | InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20) |
|---|
| InChI Key | DGBIGWXXNGSACT-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzodiazepines |
|---|
| Sub Class | 1,4-benzodiazepines |
|---|
| Direct Parent | 1,4-benzodiazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,4-benzodiazepine
- Nitroaromatic compound
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Benzenoid
- Cyclic carboximidic acid
- Ketimine
- C-nitro compound
- Organic nitro compound
- Allyl-type 1,3-dipolar organic compound
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic oxoazanium
- Organic oxygen compound
- Organochloride
- Organonitrogen compound
- Organohalogen compound
- Organic nitrogen compound
- Imine
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organooxygen compound
- Organic zwitterion
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 236.5 - 238.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.011 g/L | Not Available | | LogP | 2.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 168.2 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.7 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.9988 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.95 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 28.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1967.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 372.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 153.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 207.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 123.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 462.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 664.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 73.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1179.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 456.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1254.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 387.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 385.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 320.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 176.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 26.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Clonazepam,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=C2Cl)C2=CC([N+](=O)[O-])=CC=C21 | 2692.9 | Semi standard non polar | 33892256 | | Clonazepam,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=C2Cl)C2=CC([N+](=O)[O-])=CC=C21 | 2717.8 | Standard non polar | 33892256 | | Clonazepam,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=C2Cl)C2=CC([N+](=O)[O-])=CC=C21 | 3980.3 | Standard polar | 33892256 | | Clonazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=C2Cl)C2=CC([N+](=O)[O-])=CC=C21 | 2926.8 | Semi standard non polar | 33892256 | | Clonazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=C2Cl)C2=CC([N+](=O)[O-])=CC=C21 | 2901.6 | Standard non polar | 33892256 | | Clonazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN=C(C2=CC=CC=C2Cl)C2=CC([N+](=O)[O-])=CC=C21 | 3999.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Clonazepam GC-MS (Non-derivatized) - 70eV, Positive | splash10-02br-1190000000-1354614c337562e212cc | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Clonazepam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Clonazepam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | MS | Mass Spectrum (Electron Ionization) | splash10-02a9-2492000000-109e2626e8a128b9e433 | 2014-09-20 | Not Available | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clonazepam 10V, Positive-QTOF | splash10-014i-0009000000-f625038036279ea1ad02 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clonazepam 20V, Positive-QTOF | splash10-014i-0049000000-4dfcaef6e6f274ea9b0a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clonazepam 40V, Positive-QTOF | splash10-0a59-8911000000-fe9a4a8a76c224b6cb90 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clonazepam 10V, Negative-QTOF | splash10-03di-0009000000-cd9167e21ef0d5b8f888 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clonazepam 20V, Negative-QTOF | splash10-03di-0009000000-f28067a73f446175adef | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Clonazepam 40V, Negative-QTOF | splash10-0006-9000000000-ab88c27eceb0f144d9c2 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. [PubMed:458601 ]
- Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyken P, Sato S: Serum clonazepam concentrations in children with absence seizures. Neurology. 1975 Mar;25(3):255-8. [PubMed:1089913 ]
- Rosen GM, Turner MJ 3rd: Synthesis of spin traps specific for hydroxyl radical. J Med Chem. 1988 Feb;31(2):428-32. [PubMed:2828624 ]
- Rosen GM, Demos HA, Rauckman EJ: Not all aromatic nitro compounds form free radicals. Toxicol Lett. 1984 Aug;22(2):145-52. [PubMed:6089382 ]
- Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [PubMed:7782744 ]
|
|---|